NNC0113-5840 Clinical Trials (2026): 1 Studies for Obesity & Overweight
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 NNC0113-5840 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Obesity & Overweight) and 48 total planned enrollment. 1 NNC0113-5840 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07566390 (Nov 2026).
Where to Participate: All NNC0113-5840 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting NNC0113-5840trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | PAREXEL Glendale/LA EPCU | Glendale91206 | NCT07566390 | Map |
NNC0113-5840 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting NNC0113-5840 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07566390 | A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity | P1 | Obesity | 48 | May 2026 |
All NNC0113-5840 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07566390 | A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity | P1 | recruiting | 48 | Novo Nordisk A/S | May 2026 |
NNC0113-5840 clinical trials: frequently asked questions
- How many NNC0113-5840 clinical trials are there?
- 1 NNC0113-5840 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are NNC0113-5840 clinical trials recruiting in 2026?
- Yes — 1 NNC0113-5840 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is NNC0113-5840 being studied for?
- NNC0113-5840 is being studied for Obesity, Overweight. The trials are grouped by indication on this page.
- What phase is NNC0113-5840 in?
- NNC0113-5840 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors NNC0113-5840 clinical trials?
- The lead sponsor across the most NNC0113-5840 trials is Novo Nordisk A/S. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming NNC0113-5840as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: